Company
Synairgen PLC
LON:SNG
Synairgen PLC is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.
149 stories · page 1 of 8
Synairgen says SPRINTER trial data published, to push ahead with SNG001
Topline results were released earlier in the year
Synairgen encouraged by NIH Covid study data
America's National Institutes of Health oversaw the ACTIV-2 study to assess SNG001’s impact on home-based sufferers of the virus
Synairgen assessing three clinical options for antiviral drug
"We continue to be excited about the potential of SNG001," Richard Marsden, chief executive of the drug discovery and development company said
Synairgen to present data showing drug lowers risk of long Covid symptoms
For fatigue, the relative risk reduction was 35.4%, for shortness of breath 28.3% and for loss of smell and/or taste 61.4%
Synairgen reports positive data from respiratory viral infection drug
There was also a significant difference in the proportion of patients with detectable virus in their sputum by day seven
Synairgen to play key role in respiratory viral infection study
It will be working with US pharma group Janssen and the University of Southampton's clinical trial unit
Synairgen 'working in haste' to plan new lung infection trials
The drug developer reported result showing it had a year-end cash balance of £33.8mln